Production of β-lactamases (BLs) is the most widespread resistance mechanism adopted by bacteria to fight β-lactam antibiotics. The substrate spectrum of BLs has become increasingly broad, posing a serious health problem. Thus, there is an urgent need for novel BL inhibitors. Boronic acid transition-state analogues are able to reverse the resistance conferred by class A and C BLs. We describe a boronic acid analogue possessing interesting and potent broad-spectrum activity vs class A and C serine-based BLs. Starting from benzo(b)thiophene-2-boronic acid (BZBTH2B), a nanomolar non-β-lactam inhibitor of AmpC that can potentiate the activity of a third-generation cephalosporin against AmpC-producing resistant bacteria, we designed a novel broad-spectrum nanomolar inhibitor of class A and C BLs. Structure-based drug design (SBDD), synthesis, enzymology data, and X-ray crystallography results are discussed. We clarified the inhibitor binding geometry responsible for broad-spectrum activity vs serine-active BLs using double mutant thermodynamic cycle studies. © 2014 American Chemical Society.

Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B.K., Costi, M.P. (2014). Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. JOURNAL OF MEDICINAL CHEMISTRY, 57(12), 5449-5458 [10.1021/jm5006572].

Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative

POZZI, CECILIA;COSTI, MARIA PAOLA
2014-01-01

Abstract

Production of β-lactamases (BLs) is the most widespread resistance mechanism adopted by bacteria to fight β-lactam antibiotics. The substrate spectrum of BLs has become increasingly broad, posing a serious health problem. Thus, there is an urgent need for novel BL inhibitors. Boronic acid transition-state analogues are able to reverse the resistance conferred by class A and C BLs. We describe a boronic acid analogue possessing interesting and potent broad-spectrum activity vs class A and C serine-based BLs. Starting from benzo(b)thiophene-2-boronic acid (BZBTH2B), a nanomolar non-β-lactam inhibitor of AmpC that can potentiate the activity of a third-generation cephalosporin against AmpC-producing resistant bacteria, we designed a novel broad-spectrum nanomolar inhibitor of class A and C BLs. Structure-based drug design (SBDD), synthesis, enzymology data, and X-ray crystallography results are discussed. We clarified the inhibitor binding geometry responsible for broad-spectrum activity vs serine-active BLs using double mutant thermodynamic cycle studies. © 2014 American Chemical Society.
2014
Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B.K., Costi, M.P. (2014). Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. JOURNAL OF MEDICINAL CHEMISTRY, 57(12), 5449-5458 [10.1021/jm5006572].
File in questo prodotto:
File Dimensione Formato  
JMedChem 2014 AmpC.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 3.83 MB
Formato Adobe PDF
3.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1007305
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo